A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Latest Information Update: 29 Jan 2024
At a glance
- Drugs Crizanlizumab (Primary)
- Indications Vaso-occlusive crisis
- Focus Registrational; Therapeutic Use
- Acronyms SUSTAIN
- Sponsors Reprixys Pharmaceuticals Corporation; Selexys Pharmaceuticals
- 12 Dec 2023 Results of pooled analysis from studies (NCT0189536, NCT03264989, NCT03474965 and NCT03814746 )in patients with SCD, presented at 65th Annual Meeting and Exposition of the American Society of Hematology.
- 08 Dec 2020 Results (n=81) of post-hoc analysis assessing number of days of opioid use by patients in both the arms during 52 weeks follow-up period presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 19 Nov 2020 According to a Novartis media release, data from this trial will be presented at 62nd American Society of Hematology (ASH) Annual Meeting & Exposition